REGENXBIO to Present at Upcoming Investor Conferences

ROCKVILLE, Md., Aug. 28, 2025 /PRNewswire/ — REGENXBIO Inc. (Nasdaq: RGNX), a key player in the gene therapy space, has announced its participation in a series of upcoming investor conferences, signaling active engagement with the financial community as it progresses its pipeline of innovative therapies.

The company, known for its advancements in AAV gene therapy, will be engaging with investors and analysts at several high-profile events throughout September. These conferences will provide a platform for REGENXBIO to discuss its strategic vision, clinical progress, and the potential of its one-time treatments for rare and retinal diseases.

Here’s a breakdown of REGENXBIO’s scheduled appearances:

2025 Wells Fargo Healthcare Conference

1×1 Investor Meetings: Thursday, September 4

Location: Boston, MA

REGENXBIO will kick off its conference circuit with one-on-one meetings at the Wells Fargo Healthcare Conference. These private sessions are expected to provide in-depth discussions on the company’s pipeline and financial outlook.

Morgan Stanley 23^rd Annual Global Healthcare Conference

Fireside Chat: Monday, September 8, 2025 at 11:30 a.m. ET

Location: New York, NY

CEO [Insert CEO Name], or another key executive, is slated to participate in a fireside chat at the prestigious Morgan Stanley Global Healthcare Conference. This session is anticipated to cover key milestones, commercialization strategies, and the competitive landscape for its leading programs such as RGX-202 for Duchenne muscular dystrophy and surabgene lomparvovec (ABBV-RGX-314), in collaboration with AbbVie, for wet AMD and diabetic retinopathy.

Baird 2025 Global Healthcare Conference

Fireside Chat: Tuesday, September 9, 2025 at 8:30 a.m. ET

Location: New York, NY

Simultaneously, REGENXBIO will feature at the Baird Global Healthcare Conference with another fireside chat. This indicates a strategic focus on broadening its reach among investment firms and sharing its success stories and upcoming catalysts.

H.C. Wainwright 27^th Annual Global Investment Conference

Fireside Chat: Tuesday, September 9, 2025 at 2:30 p.m. ET

Location: New York, NY

Rounding out a busy day, REGENXBIO will also present at the H.C. Wainwright Global Investment Conference on the same day as the Baird conference. This participation underscores the company’s commitment to engaging with a diverse range of investors and analysts.

Interested investors can access live webcasts of select fireside chats via the Investors section of REGENXBIO’s website. Archived replays will be available for approximately 30 days following the presentations, giving those who cannot attend the live events an opportunity to stay informed.

REGENXBIO’s active presence at these prominent healthcare conferences underscores its commitment to transparency and engaging with the investment community as it continues to advance its gene therapy pipeline and potentially revolutionize treatment paradigms for a range of debilitating diseases. With thousands of patients already treated using REGENXBIO’s AAV platform, including those receiving Novartis’ ZOLGENSMA®, the company is poised to play a significant role in the future of healthcare. For more information, please visit WWW.REGENXBIO.COM.